PMC7907519_01
Tumor response to treatment. The metastatic mass in the posterior chest wall, before (A, D) and after (B, C, E, F) HDLRT on October 18th. (Permission by Radiation Research to extract from Figure 3 in Wu X et al..   2021 Radiation Research Society).
fonc-10-548132-g001.jpg
PMC7907519_01_fonc-10-548132-g001.jpg
f1
While the treatment was on going, the metastatic mass in the posterior chest wall grew rapidly from 2.0 cc to 63.2 cc with maximum dimensions 5.0 x 5.4 x 5.3 cm on October 10, 2017, in less than a month, (Figures 1A, D). This posterior chest wall tumor achieved complete local response (based on visual and radiographic exams) five months after the HDLRT without side effects (Figures 1B, C, E, F).
The LATTICE dose distribution in a 3D view (A); in an axial plane (B); in a sagittal plane (C); and in a coronal plane (D). The high-dose vertices (total of six) received 20 Gy to the 69% isodose line. The doses between the dose-vertices (valley) were in the order of 25% of the maximum (peak) dose. (Permission by Radiation Research to extract from Figure 3 in Wu X et al..   2021 Radiation Research Society).
fonc-10-548132-g002.jpg
PMC7907519_01_fonc-10-548132-g002.jpg
f2
The dose distribution is shown in Figure 2.
The dose-volume histograms (DVHs) of high dose-vertices, GTV, and normal tissue. D99.3% of the vertices was 20 Gy. The doses to the ribs and spinal cord were effectively minimized.
fonc-10-548132-g003.jpg
PMC7907519_01_fonc-10-548132-g003.jpg
f3
The dose-volume histograms (DVHs) of the high-dose vertices, GTV, ribs, and spinal cord were shown in Figure 3.
(A) Dose distribution in a coronal plane. The peak-valley dose profile (B) along the green line marked in panel (A), showing the peak to valley dose ratio of about 4. (Permission by Radiation Research to extract from Figure 3 in Wu X et al..   2021 Radiation Research Society).
fonc-10-548132-g004.jpg
PMC7907519_01_fonc-10-548132-g004.jpg
f4
The Peak-to-Valley dose profile (Figure 4) showed the valley dose between vertices to be about 25% of the peak dose.